Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only,
option for the treatment of leukemia, particularly for patients with advanced-stage leukemia.
However, relapse rate was still very high for advanced-stage leukemia.
It was found in our previous study that infusion of granulocyte colony-stimulating factor
(G-CSF)-primed peripheral blood progenitor cells (GPBPC) instead of non-primed lymphocytes
exhibited a comparative or stronger graft-versus-leukemia (GVL) effect and comparative or
less incidence of GVHD, rarely being complicated with pancytopenia. When GPBPC infusion was
combined with the use of short-term immunosuppressant for GVHD prophylaxis, the incidence of
fatal GVHD complicated with GPBPCI was further reduced. Our primary data showed the GPBPCI
combined with the use of short-term immunosuppressant was feasible in patients with advanced
leukemia to prevent relapse after HLA-mismatched HSCT.
The study hypothesis:
Prevention of relapse using granulocyte colony-stimulating factor-primed peripheral blood
progenitor cells following hematopoietic stem cell transplantation in patients with
advanced-stage acute leukemia can
- reduce relapse rate
- improve survival